EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Glial modulators as novel therapeutics for comorbid pain and opioid use disorder

Elizabeth K C Schwartz iD, Joao P De Aquino, Mehmet Sofuoglu iD

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16094 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Elizabeth K C Schwartz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Chronic Pain, Analgesics, Opioid, Neuroglia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 111 Literaturangaben. Gefördert von: NIDA NIH HHS, VISN 1 MIRECC, National Institute of Development Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic pain and opioid use disorder (OUD) are major public health problems, with rising opioid‐related overdose deaths linked to increased opioid prescriptions for pain management. Novel treatment approaches for these commonly comorbid disorders are needed. Growing evidence supports a role for glial activation for both chronic pain and substance use disorders, including OUD. This review provides an overview of glial modulators as a novel treatment approach for comorbid pain and OUD. We aim to synthesize clinical studies investigating the efficacy of glial modulators in treating these comorbid disorders. We conducted a literature search of PubMed and Google Scholar databases in October 2023 to identify relevant clinical trials. The included studies varied in terms of patient population, study methodology and outcomes assessed, and were often limited by small sample sizes and other methodological issues. Additionally, several glial modulators have yet to be studied for chronic pain and OUD. Despite these limitations, these studies yielded positive signals that merit further investigation. Both chronic pain and OUD remain significant public health problems, with many treatment challenges. Glial modulators continue to hold promise as novel therapeutics for comorbid pain and OUD, given positive indications that they can improve pain measures, and reduce addiction‐related outcomes. As our understanding of the mechanisms underlying the contributions of glial modulators to pain and addiction behaviours deepens, we will be better equipped to identify more specific therapeutic targets for chronic pain and OUD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersChronic PainAnalgesics, OpioidNeurogliaHumansAnimalsComorbidity

Stichwörter der Autor:innen

analgesiadrug developmentglial modulatorsnociceptionopioid addiction

Substanzen

Analgesics, Opioid

Autor:innen und Institutionen

  • Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
  • VA Connecticut Healthcare System, West Haven, Connecticut, USA.
  • Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, Connecticut, USA.

ORCID-Profile: Elizabeth K C Schwartz, Mehmet Sofuoglu

Förderung

  • NIDA NIH HHS
  • VISN 1 MIRECC
  • National Institute of Development Administration

Zitieren

APA

Schwartz, E. K. C., De Aquino, J. P., & Sofuoglu, M. (2024). Glial modulators as novel therapeutics for comorbid pain and opioid use disorder. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16094

Vancouver

Schwartz EKC, De Aquino JP, Sofuoglu M. Glial modulators as novel therapeutics for comorbid pain and opioid use disorder. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16094

BibTeX
@article{Schwartz2024,
  author = {Schwartz, Elizabeth K C and De Aquino, Joao P and Sofuoglu, Mehmet},
  title = {Glial modulators as novel therapeutics for comorbid pain and opioid use disorder},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16094}
}
Kostenlos starten →